Chromatin-Modifying Drugs and HDAC Inhibitors

Because epigenetic marks are written and erased by enzymes, they can be targeted with drugs. Chromatin-modifying agents — most prominently histone deacetylase (HDAC) inhibitors and DNA-methyltransferase inhibitors — aim to reverse the abnormal silencing of genes in cancer by reshaping the chromatin and methylation landscape. This topic explains how these agents act on the epigenetic machinery rather than on the DNA sequence.

Definition

Chromatin-modifying drugs are agents that alter the epigenetic state of the genome by inhibiting the enzymes that maintain repressive chromatin or DNA methylation; HDAC inhibitors are the major class that block histone deacetylases, promoting histone acetylation and a more open, transcriptionally permissive chromatin state.

Scope

The entry covers the rationale for epigenetic therapy, the two principal drug classes (HDAC inhibitors and DNA-methyltransferase inhibitors), their mechanism of reactivating silenced genes, and the concept of pharmacological reversal of epigenetic states. It is an educational reference on mechanism, not a prescribing or treatment guide; no dosing is given.

Core questions

• Why does the reversibility of epigenetic marks make them druggable?
• How do HDAC inhibitors reactivate silenced genes?
• How do DNA-methyltransferase inhibitors differ from HDAC inhibitors?
• Why might the two classes be combined?

Key concepts

• Epigenetic therapy
• Histone deacetylase (HDAC) inhibition
• Histone acetylation and open chromatin
• DNA-methyltransferase inhibitors
• Reactivation of silenced genes
• Pharmacological reversibility of epigenetic marks

Mechanisms

Histone deacetylases remove acetyl groups from histones, tightening chromatin and repressing transcription. HDAC inhibitors block this removal, so histones remain acetylated, chromatin loosens, and previously silenced genes — including some tumour-suppressor and pro-apoptotic genes — can be re-expressed. DNA-methyltransferase inhibitors work by a complementary route, preventing the maintenance of DNA methylation so that hypermethylated promoters lose their silencing marks across cell divisions. Because both classes target enzymes that act on chromatin rather than on the DNA sequence, they exploit the reversibility of epigenetic states, and the two are sometimes combined to reactivate genes silenced by both methylation and deacetylation.

Clinical relevance

Several HDAC inhibitors and DNA-methyltransferase inhibitors have been developed as anticancer agents, illustrating the translation of epigenetic biology into therapy. This entry describes their mechanism of action for educational orientation only; it gives no dosing and is not a basis for individual treatment decisions.

History

The discovery that compounds such as dimethyl sulfoxide derivatives could induce differentiation led Marks and Breslow to develop vorinostat, a defining HDAC inhibitor, while parallel work established DNA-methyltransferase inhibitors as agents that reverse promoter hypermethylation. Johnstone and colleagues characterised the anticancer activities of HDAC inhibitors, and Baylin and Jones traced how these agents matured into clinical epigenetic therapy over a decade.

Debates

How is the selectivity of chromatin-modifying drugs achieved?

Because HDAC and DNA-methyltransferase inhibitors act on machinery used genome-wide, why their effects appear relatively selective for malignant cells — and how to improve that selectivity — remains an active question.

Key figures

• Paul A. Marks
• Ronald Breslow
• Ricky W. Johnstone
• Stephen Baylin
• Jean-Pierre Issa

Seminal works

• bolden-2006
• marks-breslow-2007
• baylin-jones-2011

Frequently asked questions

What does an HDAC inhibitor actually do?

It blocks the enzymes that remove acetyl groups from histones, so histones stay acetylated and chromatin stays open, allowing genes that had been silenced to be expressed again.

Why are epigenetic marks considered good drug targets?

Unlike DNA mutations, methylation and histone modifications are added and removed by enzymes, so drugs that inhibit those enzymes can in principle reverse an abnormal epigenetic state.